close
Home
Europe's Choice
News & Events
chevron_right
About medicines
chevron_right
More Than Medicine
chevron_right
Relationships & code
chevron_right
Publications
chevron_right
About us
chevron_right
Contact us
KMS Login
arrow_back
close
Europe's Choice
News & Events
The EFPIA View
Events
Newsletter
About medicines
Development of medicines
expand_more
expand_less
chevron_right
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Environment, Health, Safety & Sustainability
Use of medicines
expand_more
expand_less
chevron_right
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
expand_more
expand_less
chevron_right
Back Innovation, Boost Access
More Than Medicine
Improving Health
Turning science into new medicines
Responsible Innovation
Economic impact
Relationships & code
The EFPIA Code
Patient organisations
Healthcare professionals (HCPs)
Disclosure of payments
National codes
EU institutions
Publications
Data center
Downloads
Cancer Comparator Report 2025
expand_more
expand_less
chevron_right
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
About us
Who we are
EFPIA Japan
Membership
Job vacancies
Partnerships & Initiatives
Contact us
arrow_back
close
Development of medicines
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Environment, Health, Safety & Sustainability
Use of medicines
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
Back Innovation, Boost Access
Cancer Comparator Report 2025
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
WeWontRest
Patient stories
...
close
Filter by
Disease area
Access
Alzheimer's
AMR
Arthritis
Asthma
Atopic Dermatitis
Blood cancer
Cardiovascular
Clinical trials
Collaboration
Crohn's disease
Diabetes
eHealth
General
Haemophilia
Hepatitis C
HIV
Innovation
Lung cancer
Migraine
Multiple Sclerosis
Oncology
Osteoporosis
Outcomes
Parkinson's
Patients
Patient Engagement
Pediatrics
Rare Diseases
Vaccines
Cardiovascular disease
Organisation
AbbVie
AIFP
Allergan
Amgen
APIFARMA
Astellas
Bayer
Bial
Biogen
Bristol-Myers Squibb (BMS)
Boehringer Ingelheim
Celgene
Curevac
EBE
EFPIA
Eisai Europe
Grunenthal
Menarini
GSK
IFPMA
Ipsen
Janssen
Johnson & Johnson
Lilly
Merck
MSD
Novartis
Pfizer
Pharmacists' Association
PharmaMar
Pharmig
Pierre Fabre
Roche
Sanofi
Servier
Shield Therapeutics
Shire
Sylentis
Takeda
TiGenix
UCB
Valormed
Vifor Pharma
IFPMA
Byondis
Vaccines Europe
AM Pharma
Country
Austria
Belgium
Brazil
Canada
China
Czech Republic
Denmark
Europe
Finland
France
Germany
Hungary
Ireland
Italy
Latvia
Netherlands
Norway
Poland
Portugal
Romania
Russia
Spain
Switzerland
Sweden
Turkey
UK
USA
AM Pharma
Clear filters
print
Print
Load more
Back to top
close
continue